CXCR1/2 chemokine network regulates melanoma resistance to chemotherapies mediated by NF-κB

S. Wu, S. Saxena, M. L. Varney, Rakesh K Singh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Cancer-related inflammation is recognized as a driver for tumor progression and chemokines are important players in both inflammation and the progression of many cancer types. CXC chemokines, especially CXCL8, have been implicated in melanoma growth and metastasis, while less is known for their roles in drug resistance. Methods: We generated drug-resistant cells by continuous exposure to chemotherapeutic drugs and analyzed the mechanism(s) of therapy resistance in malignant melanoma. Results: We report chemotherapies induced upregulation of a variety of chemokines in the CXCR1/CXCR2 network by an NF-kB-dependent mechanism. Notably, analysis of the drug-resistant melanoma cell line selected after prolonged exposure to chemotherapeutic drug dacarbazine revealed higher levels of CXCL8 and CXCR2 compared with parent cells as a signature of drug resistance. CXCR2 neutralization markedly improved sensitivity to dacarbazine in melanoma cells. Conclusion: These data provide insights into what drives melanoma cells to survive after chemotherapy treatment, thus pointing to strategies for developing combined drug therapies for combating the problem of chemotherapy resistance in melanoma.

Original languageEnglish (US)
Pages (from-to)436-449
Number of pages14
JournalCurrent Molecular Medicine
Volume17
Issue number6
DOIs
StatePublished - Jul 1 2017

Fingerprint

Chemotherapy
Chemokines
Melanoma
Drug Therapy
Pharmaceutical Preparations
Dacarbazine
Drug Resistance
Inflammation
Drug therapy
CXC Chemokines
Neoplasms
NF-kappa B
Interleukin-8
Tumors
Up-Regulation
Cells
Neoplasm Metastasis
Cell Line
Therapeutics
Growth

Keywords

  • Chemotherapy
  • CXCR1
  • CXCR2
  • Melanoma
  • NF-κB
  • Resistance

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

CXCR1/2 chemokine network regulates melanoma resistance to chemotherapies mediated by NF-κB. / Wu, S.; Saxena, S.; Varney, M. L.; Singh, Rakesh K.

In: Current Molecular Medicine, Vol. 17, No. 6, 01.07.2017, p. 436-449.

Research output: Contribution to journalArticle

@article{2ec32c6fd26a43d7adb907b2a38d5284,
title = "CXCR1/2 chemokine network regulates melanoma resistance to chemotherapies mediated by NF-κB",
abstract = "Background: Cancer-related inflammation is recognized as a driver for tumor progression and chemokines are important players in both inflammation and the progression of many cancer types. CXC chemokines, especially CXCL8, have been implicated in melanoma growth and metastasis, while less is known for their roles in drug resistance. Methods: We generated drug-resistant cells by continuous exposure to chemotherapeutic drugs and analyzed the mechanism(s) of therapy resistance in malignant melanoma. Results: We report chemotherapies induced upregulation of a variety of chemokines in the CXCR1/CXCR2 network by an NF-kB-dependent mechanism. Notably, analysis of the drug-resistant melanoma cell line selected after prolonged exposure to chemotherapeutic drug dacarbazine revealed higher levels of CXCL8 and CXCR2 compared with parent cells as a signature of drug resistance. CXCR2 neutralization markedly improved sensitivity to dacarbazine in melanoma cells. Conclusion: These data provide insights into what drives melanoma cells to survive after chemotherapy treatment, thus pointing to strategies for developing combined drug therapies for combating the problem of chemotherapy resistance in melanoma.",
keywords = "Chemotherapy, CXCR1, CXCR2, Melanoma, NF-κB, Resistance",
author = "S. Wu and S. Saxena and Varney, {M. L.} and Singh, {Rakesh K}",
year = "2017",
month = "7",
day = "1",
doi = "10.2174/1566524018666171219100158",
language = "English (US)",
volume = "17",
pages = "436--449",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - CXCR1/2 chemokine network regulates melanoma resistance to chemotherapies mediated by NF-κB

AU - Wu, S.

AU - Saxena, S.

AU - Varney, M. L.

AU - Singh, Rakesh K

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background: Cancer-related inflammation is recognized as a driver for tumor progression and chemokines are important players in both inflammation and the progression of many cancer types. CXC chemokines, especially CXCL8, have been implicated in melanoma growth and metastasis, while less is known for their roles in drug resistance. Methods: We generated drug-resistant cells by continuous exposure to chemotherapeutic drugs and analyzed the mechanism(s) of therapy resistance in malignant melanoma. Results: We report chemotherapies induced upregulation of a variety of chemokines in the CXCR1/CXCR2 network by an NF-kB-dependent mechanism. Notably, analysis of the drug-resistant melanoma cell line selected after prolonged exposure to chemotherapeutic drug dacarbazine revealed higher levels of CXCL8 and CXCR2 compared with parent cells as a signature of drug resistance. CXCR2 neutralization markedly improved sensitivity to dacarbazine in melanoma cells. Conclusion: These data provide insights into what drives melanoma cells to survive after chemotherapy treatment, thus pointing to strategies for developing combined drug therapies for combating the problem of chemotherapy resistance in melanoma.

AB - Background: Cancer-related inflammation is recognized as a driver for tumor progression and chemokines are important players in both inflammation and the progression of many cancer types. CXC chemokines, especially CXCL8, have been implicated in melanoma growth and metastasis, while less is known for their roles in drug resistance. Methods: We generated drug-resistant cells by continuous exposure to chemotherapeutic drugs and analyzed the mechanism(s) of therapy resistance in malignant melanoma. Results: We report chemotherapies induced upregulation of a variety of chemokines in the CXCR1/CXCR2 network by an NF-kB-dependent mechanism. Notably, analysis of the drug-resistant melanoma cell line selected after prolonged exposure to chemotherapeutic drug dacarbazine revealed higher levels of CXCL8 and CXCR2 compared with parent cells as a signature of drug resistance. CXCR2 neutralization markedly improved sensitivity to dacarbazine in melanoma cells. Conclusion: These data provide insights into what drives melanoma cells to survive after chemotherapy treatment, thus pointing to strategies for developing combined drug therapies for combating the problem of chemotherapy resistance in melanoma.

KW - Chemotherapy

KW - CXCR1

KW - CXCR2

KW - Melanoma

KW - NF-κB

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85043305466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043305466&partnerID=8YFLogxK

U2 - 10.2174/1566524018666171219100158

DO - 10.2174/1566524018666171219100158

M3 - Article

VL - 17

SP - 436

EP - 449

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 6

ER -